|Description||UPF 1069 is a selective PARP2 inhibitor with IC50 of 0.3 μM. It is ~27-fold selective against PARP1.PARP activity is evaluated by utilizing commercially available recombinant bovine PARP-1 and mouse PARP-2. Briefly|
BYK 204165 is a potent and selective poly(ADP-ribose) polymerase (PARP)-1 inhibitor (pIC50 = 5.38 and 7.35 for PARP-2 and PARP-1, respectively). BYK 204165 is 1...
Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a ...
Protease-Activated Receptor-2, amide, also known as SLIGKV-NH2, is a highly potent protease-activated receptor-2 (PAR2) activating peptide and can also be utliz...
MK-4827 (R-enantiomer) is the R form of MK-4827, which is a PARP inhibitor developed for the treatment of ovarian cancer.
PJ34 is a novel and potential PARP inhibitor with potential anticancer activity. PJ34 has a high affinity for PARP-1 (IC(50) = 20 nM) .
Rucaparib, also known as (AG-14699 or PF-01367338, is a tricyclic indole poly(ADP-Ribose) polymerase (PARP1) inhibitor with potential chemosensitizing, radiose...
A novel small-molecule-like BRCA1 inhibitor (IC50= 0.53 μM) (Ki= 0.71 μM)
PJ34 is a potent specific inhibitor of PARPl/2 with IC50 of 110 nM and 86 nM, respectively.